Biodesix to Present at TD Cowen 45th Annual Health Care Conference
Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has announced its participation in the TD Cowen 45th Annual Health Care Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on March 5, 2025.
The presentation is scheduled for 1:50 PM ET in Boston, MA. Investors and interested parties can access the live webcast and replay through the 'News & Events' section of the Investors page on biodesix.com.
Details
News Market Reaction – BDSX
The recorded move for BDSX in the trading session of this news was +3.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025.
TD Cowen 45th Annual Health Care Conference
Fireside Chat Date: Wednesday, March 5, 2025
Fireside Chat Time: 1:50 PM ET
Location: Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for pulmonology patients. The Nodify Lung® Nodule Risk Assessment evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The IQLung™ test portfolio for lung cancer patients supports treatment decisions across all stages of lung cancer and expedites personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
chris.brinzey@icrhealthcare.com
1-339-970-284
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.